Risk-Based Oversight Redefined: How E6R3 is Reshaping Vendor Governance
At the SCOPE Europe 2025 conference, industry experts underscored how ICH E6(R3) is transforming the way sponsors approach vendor...
Imaging as Infrastructure: Why Sponsors Must Rethink Oversight in Modern Trials
At DPHARM, we spoke with Paul McCracken, founder and principal of RadiaNova Consulting, about the overlooked pitfalls in clinical...
CRB-701: Remarkable Clinical Responses in HNSCC Cancers
At the 3.6 mg/kg dose of CRB-701, Corbus reported objective response rates of 47.6% in head and neck squamous...
Olema Announces New Data from Palazestrant Cancer Trial
Median PFS reached 15.5 months in the 120 mg palazestrant cohort across all comers, with 12.2 months among patients...
Disc Medicine Presents New Phase 1b CKD/Anemia Trial Data
Disc Medicine will deliver a full Phase 1b update of DISC-0974 in non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with...
AI Cancer Vaccine Shows Surging 75% Response in Phase 2 Trial
Evaxion reported a 75% objective response rate in a 16-patient Phase 2 study of EVX-01 plus pembrolizumab in first-line...
FDA Approves Junshi’s New Phase 2/3 NSCLC Clinical Study
Junshi Biosciences has received FDA IND clearance to initiate an international, open-label, randomized phase 2/3 study testing its PD-1/VEGF...
NEJM Publishes Successful China Phase 3 Lupus Drug Data
Telitacicept produced a 67.1% modified SRI-4 response at week 52 versus 32.7% on placebo (P<0.001) in a 335‑patient Phase...
Surging DNA Cancer Vaccine Market: Trials & FDA Insight
First approval for a DNA cancer vaccine could land by 2030, with more than 20 candidates now in clinical...
ANI Pharma to Present New Day Clinical Trial Data at AAO 2025
No new efficacy or safety figures were disclosed in today’s announcement, but ANI Pharmaceuticals will showcase the already reported...